SDC 1801
Alternative Names: SDC-1801Latest Information Update: 28 Jan 2025
At a glance
- Originator Sareum
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Antivirals; Small molecules
- Mechanism of Action Janus kinase 1 inhibitors; TYK2 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Autoimmune disorders; COVID 2019 infections; COVID-19 pneumonia; Inflammatory bowel diseases; Multiple sclerosis; Psoriasis; Rheumatoid arthritis
Most Recent Events
- 28 Jan 2025 No recent reports of development identified for research development in COVID-19 pneumonia in United Kingdom
- 28 Jan 2025 No recent reports of development identified for research development in COVID-2019-infections in United Kingdom
- 28 Jul 2024 No recent reports of development identified for preclinical development in Autoimmune-disorders in United Kingdom